Lewis Y antigen expression and postoperative survival in non–small cell lung cancer Fumihiro Tanaka, MD, Ryo Miyahara, MD, Yohsuke Ohtake, MD, Kazuhiro.

Slides:

Advertisements

Similar presentations

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Advertisements

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Thomas J. Birdas, MD, Richard P. M

Malignant minor pleural effusion detected on thoracotomy for patients with non–small cell lung cancer: is tumor resection beneficial for prognosis? Noriyoshi.

A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer Shinjiro.

Quality of life after tailored combined surgery for stage I non–small-cell lung cancer and severe emphysema Eugenio Pompeo, MD, Enrico De Dominicis,

Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers Yung-Chie Lee, MD, PhD, Yih-Leong Chang, MD, Shi-Ping.

Lung cancer staging and treatment in multidisciplinary trials: cancer and leukemia group B cooperative group approach1 Mark J Krasna, MD, Carolyn E Reed,

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,

Surgical Results and Prognostic Factors in Early Non–Small Cell Lung Cancer José Padilla, MD, Vı́ctor Calvo, MD, Juan C Peñalver, MD, Gabriel Sales, MD,

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience Tsuguo Naruke,

Meta-Analysis of Positron Emission Tomographic and Computed Tomographic Imaging in Detecting Mediastinal Lymph Node Metastases in Nonsmall Cell Lung Cancer

Ki-67 expression and prognosis for smokers with resected stage i Non–Small cell lung cancer Yukiko Haga, MD, Kenzo Hiroshima, MD, Akira Iyoda, MD, Kiyoshi.

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer Masatsugu Hamaji, MD, Mark S. Allen,

Surgical Treatment of Metachronous Second Primary Lung Cancer

Survival related to lymph node involvement in lung cancer after sleeve lobectomy compared with pneumonectomy Morihito Okada, MD, Hiroyuki Yamagishi,

Surgical treatment of non-small cell lung cancer 1 cm or less in diameter Daniel L Miller, MD, Charles M Rowland, MS, Claude Deschamps, MD, Mark S Allen,

Thomas J. Birdas, MD, Richard P. M

Andrea S. Wolf, MD, William G. Richards, PhD, Michael T

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic.

Prognostic factors in clinical stage I non–small cell lung cancer

Preoperative evidence of circulating tumor cells by means of reverse transcriptase- polymerase chain reaction for carcinoembryonic antigen messenger RNA.

Bilobectomy for Lung Cancer: Analysis of Indications, Postoperative Results, and Long- Term Outcomes Domenico Galetta, MD, PhD, Piergiorgio Solli, MD,

Elliot Wakeam, MD, MPH, James P. Byrne, MD, Gail E

Lorenzo Spaggiari, MD, PhD, Ugo Pastorino, MD

Better pulmonary function and prognosis with video-assisted thoracic surgery than with thoracotomy Shizuka Kaseda, MD, Teruhiro Aoki, MD, Nanae Hangai,

Number of Lymph Nodes Associated With Maximal Reduction of Long-Term Mortality Risk in Pathologic Node-Negative Non–Small Cell Lung Cancer Raymond U.

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

The Prognostic Value of the Number of Negative Lymph Nodes in Esophageal Cancer Patients After Transthoracic Resection Po-Kuei Hsu, MD, Chien-Sheng Huang,

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Results of surgical intervention for p-stage IIIA (N2) non–small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with.

Prognostic assessment of 1310 patients with non–small-cell lung cancer who underwent complete resection from 1980 to 1993 Kunihiko Inoue, MDa, Masami.

Valerie W Rusch, MD, Ennapadam S Venkatraman, PhD

Pulmonary Resection for Lung Cancer in Octogenarians

Prognostic significance of surgical-pathologic N1 disease in non-small cell carcinoma of the lung Marc Riquet, MD, Dominique Manac’h, MD, Françoise Le.

Pulmonary Sclerosing Hemangioma With Metastasis to the Mediastinal Lymph Node Hiromichi Katakura, MD, Manami Sato, MD, Fumihiro Tanaka, MD, Hiroaki Sakai,

Selective Mediastinal Lymphadenectomy for Clinico-Surgical Stage I Non–Small Cell Lung Cancer Morihito Okada, MD, PhD, Toshihiko Sakamoto, MD, PhD, Tsuyoshi.

Time trends and survival after operations for primary lung cancer from 1976 through 1990 Hiromi Wada, MD, Fumihiro Tanaka, MD, Kazuhiro Yanagihara, MD,

Number of Metastatic Lymph Nodes in Resected Non–Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD,

Douglas E. Paull, MD, Glenda M. Updyke, PA-C, Michael A

Preoperative Chemotherapy Does Not Increase Complications After Nonsmall Cell Lung Cancer Resection Emilie Perrot, MD, Benoit Guibert, MD, Pierre Mulsant,

Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures Noriaki Sakakura, MD, Shoichi Mori, MD, Futoshi Ishiguro,

Distribution and Likelihood of Lymph Node Metastasis Based on the Lobar Location of Nonsmall-Cell Lung Cancer Robert J. Cerfolio, MD, Ayesha S. Bryant,

Carcinoma of the esophagus: Prognostic significance of histologic type

Lymph Node Staging by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Patients With Small Cell Lung Cancer Hironobu Wada, MD, Takahiro.

Edwin van Velzen, MD, Aart Brutel de la Rivière, MD, PhD, Hans J

Optimal distance of malignant negative margin in excision of nonsmall cell lung cancer: a multicenter prospective study Noriyoshi Sawabata, MD, Mitsunori.

Neal S Goldstein, MD The Annals of Thoracic Surgery

Relevance of Lymph Node Micrometastases in Radically Resected Endobronchial Carcinoid Tumors Tommaso Claudio Mineo, MD, Gianluca Guggino, MD, Davide.

Mert Saynak, MD, Jessica Hubbs, MS, Jiho Nam, MD, Lawrence B

Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer Steven M Keller, MD, Sudeshna Adak,

Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer Bernward Passlick, MD, Boris Kubuschok, MD,

Nonanatomic prognostic factors in resected nonsmall cell lung carcinoma: the importance of perineural invasion as a new prognostic marker Adnan Sayar,

Walter J. Scott, MD, James Shepherd, MS, Sanjiv Sam Gambhir, MD, PhD

Aritoshi Hattori, MD, Kenji Suzuki, MD

Who should decide margin length in pulmonary excision of lung cancer?

Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study Robert J. Cerfolio, MD, Ayesha.

Mark I. Block, MD The Annals of Thoracic Surgery

Is there a benefit to continuing with resection of all sites of disease when clinically occult pleural metastases from non–small cell carcinoma are found?

Tracheobronchoplasty for resection of lung cancer arising from a tracheal bronchus Masaaki Sato, MD, Seiki Hasegawa, MD, PhD, Tsuyoshi Shoji, MD, Hiromi.

A phase II single-institution study of neoadjuvant stage IIIA/B chemotherapy and radiochemotherapy in non-small cell lung cancer Andreas Granetzny, MD,

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Presentation transcript:

Lewis Y antigen expression and postoperative survival in non–small cell lung cancer Fumihiro Tanaka, MD, Ryo Miyahara, MD, Yohsuke Ohtake, MD, Kazuhiro Yanagihara, MD, Tatsuo Fukuse, MD, Shigeki Hitomi, MD, Hiromi Wada, MD The Annals of Thoracic Surgery Volume 66, Issue 5, Pages 1745-1750 (November 1998) DOI: 10.1016/S0003-4975(98)00937-0

Fig 1 Survival after complete tumor resection with lymph node dissection for non–small cell lung cancer during 1985–1990 at Kyoto University. Comparison between that for Lewis Y antigen (LeYLeY) expression positive disease and that for LeY expression negative disease. The Annals of Thoracic Surgery 1998 66, 1745-1750DOI: (10.1016/S0003-4975(98)00937-0)

Fig 2 Survival after complete tumor resection with lymph node dissection for non–small cell lung cancer during 1985–1990 at Kyoto University. Comparison between that for Lewis Y antigen (LeY) expression positive disease and that for LeY expression negative disease. The Annals of Thoracic Surgery 1998 66, 1745-1750DOI: (10.1016/S0003-4975(98)00937-0)

Fig 3 Comparison of postoperative survival between LeY-positive and p53 aberrant expression negative disease (A), that for LeY-positive and p53 aberrant expression positive disease (B), that for LeY-negative and p53 aberrant expression negative disease (C), and that for LeY-negative and p53 aberrant expression positive disease (D). The Annals of Thoracic Surgery 1998 66, 1745-1750DOI: (10.1016/S0003-4975(98)00937-0)

Fig 4 Comparison of postoperative survival for p-stage 1, NSCLC between LeYpositive and p53 aberrant expression negative disease (A), that for LeY-positive and p53 aberrant expression positive disease (B), that for LeY-negative and p53 aberrant expression negative disease (C), and that for LeY-negative and p53 aberrant expression positive disease (D). The Annals of Thoracic Surgery 1998 66, 1745-1750DOI: (10.1016/S0003-4975(98)00937-0)

The Annals of Thoracic Surgery 1998 66, 1745-1750DOI: (10 The Annals of Thoracic Surgery 1998 66, 1745-1750DOI: (10.1016/S0003-4975(98)00937-0)